Compositions and methods for treating surgical mesh exposure
PEP, a purified exosome product, addresses surgical mesh exposure by enhancing epithelial proliferation and vascularization, offering a non-surgical solution to reduce mesh exposure and related complications.
Patent Information
- Application Number
- JP2024532717
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-30
- Publication Date
- 2024-12-03
AI Technical Summary
Surgical mesh exposure, which often occurs due to inadequate wound healing, leads to complications such as dyspareunia, vaginal infections, and the need for costly reoperations, with existing treatments like vaginal estrogen lacking strong evidence for efficacy and surgical interventions being risky.
Administering PEP, a purified exosome product, to the tissue adjacent to exposed surgical mesh to enhance epithelial proliferation, vascularization, and tissue thickness, either alone or in conjunction with surgical closure, to promote healing.
PEP effectively reduces mesh exposure by increasing epithelial thickness, vascularization, and reducing scar formation, potentially eliminating the need for surgical interventions and improving wound healing outcomes.
Smart Images

Figure 2024544662000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 284,987, filed December 01, 2021, which is incorporated by reference in its entirety.
[0002] government funding This invention was made with Government support under TR002377 awarded by the National Center for Advancing Translational Studies under the National Institutes of Health. The Government has certain rights in this invention. Summary of the Invention
[0003] The present disclosure, in one aspect, describes a method for treating an exposed surgical mesh in a subject. In general, the method comprises administering a PEP to tissue adjacent to an area of exposed surgical mesh in an amount effective to treat the area of exposed surgical mesh.
[0004] In another aspect, the present disclosure describes a method for treating an exposed surgical mesh in a subject. In general, the method includes surgically closing an area of exposed surgical mesh and administering a PEP to the epithelium adjacent to the surgical closure in an amount effective to treat the area of exposed surgical mesh.
[0005] In one or more embodiments of any aspect, an amount effective to treat an area of exposed surgical mesh can be an amount effective to increase epithelial proliferation to reduce the area of exposed surgical mesh, to increase the thickness of the epithelium overlying the surgical mesh, or to increase vascularization of the epithelium overlying the surgical mesh.
[0006] In one or more embodiments of either aspect, the PEP is administered once. In other embodiments, the PEP is administered two or more times.
[0007] In one or more embodiments of any aspect, the PEP has at least 10 12 The PEP exosomes are administered in an amount effective to deliver the exosomes.
[0008] In one or more embodiments of any aspect, the surgical mesh is at least 1 cm by 1 cm in size.
[0009] In one or more embodiments of any aspect, the method results in resolution of mesh exposure as measured by increased cell proliferation, increased epithelial thickness, increased vascularization, or lack of dehiscence compared to untreated mesh exposure.
[0010] In one or more embodiments of any aspect, the method results in reduced scar formation as measured by histomicroscopy compared to exposure of the untreated mesh.
[0011] The above summary is not intended to describe each disclosed embodiment or every implementation of the present invention. The following description more particularly exemplifies illustrative embodiments. In several places throughout this application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list. [Brief description of the drawings]
[0012] [Figure 1]Experimental Method: Model Creation and Intervention. (A) Creation of mesh exposure model. Day 0: Vagina is denuded and mesh is implanted. All animals underwent initial surgery to create mesh model. Vagina was denuded according to planned mesh implant size. Mesh was fixed with sutures. Group 1 had two 3×3 centimeter (cm) meshes implanted in the ventral and rostral vagina. Group 2 had three meshes of different sizes implanted circumferentially: 1×2 cm, 2×2 cm, and 3×3 cm. One animal in this group that received EdU had two 3×3 cm implants rather than different sized meshes. (B) Intervention on Day 7: Surgical closure. Four animals in group 1 underwent a second surgery to mobilize vaginal epithelium and close vaginal tissue over the underlying mesh in an interrupted fashion (left). Half of these animals received PEP injections at the same time (group 1B). Three animals in group 2 received injections of PEP only (right; group 2). Abbreviations: PEP, purified exosomal product; EdU, 2'-deoxy-5-ethynyluridine.
[0013] [Diagram 2] Gross lesions and transmission electron microscopy (TEM). (A) Gross vagina-mesh complex 4 weeks after the first surgery. Panel 1: wild type, uninstrumented porcine vagina. Panel 2: Group 1A, surgical closure only. Panel 3: Group 1B, PEP injection with surgical closure. Panel 4: Group 2, PEP injection only. The white dashed box represents the area of underlying mesh. All meshes depicted are 3×3 cm. (B) Transmission electron microscopy: wild type represents healthy porcine vagina at the epithelial level (top; 1500x magnification), and deeper into the dermis, focused at the level of the basement membrane (middle and bottom; 3,000x and 12,000x). Group 1A, which underwent surgical closure only, had squamous epithelial cells with disrupted cellular organization adjacent to the intermittently disrupted basement membrane (middle panel). Group 2, treated with PEP only, had epithelial cells with normal architecture and cell junctions, with some scattered inflammatory cells (top right, 3000x), while the basement membrane and adjacent cellular organization were preserved (right, center and bottom).
[0014] [Diagram 3] Histological evaluation of the vagina-mesh complex. (A) Representative Masson's trichrome staining of explants obtained at the time of sacrifice. (B) Representative immunofluorescence images showing the epithelial markers cytokeratin and stromal collagen III. (C) Representative immunofluorescence images showing proliferating (Ki67+) cells within the epithelium (cytokeratin) and underlying dermal tissue.
[0015] [Figure 4] Histological evaluation of the vagina-mesh complex. (A) Quantification of epithelial thickness obtained from Masson's Trichrome staining. ANOVA p=0.03. (B) Quantification of total proliferation, epithelial proliferation and non-epithelial proliferation (Ki67+) cells per epithelial length. For (A) and (B), n=2 (wild type, non-operated vaginal tissue), n=2 (surgical closure only), n=4 (PEP with surgical closure), n=7 for A and n=5 for E (PEP injection only). (C) EdU is present in cells throughout the epithelium and underlying tissue, confirming de novo regeneration during the 4-week healing period. Values are expressed as mean ± SEM.
[0016] [Diagram 5] Cellular analysis of the vagina-mesh complex. (A) Representative immunofluorescence images of CD3+ T cells adjacent to E-cadherin+ (E-Cad) epithelium. (B) Representative immunofluorescence images showing the presence of angiogenesis (CD31+ endothelial cells (SMA+ smooth muscle cells) surrounded by smooth muscle actin) as well as myofibroblasts (extravascular SMA+ areas).
[0017] [Figure 6]Cellular analysis of the vagina-mesh complex. (A) Quantification of T cell abundance by relative CD3+ fraction per high power field. (B) Quantification of angiogenesis (CD31+ lumen per mm2). ANOVA p=0.03, *p<0.05 vs. wild type. (C) Quantification of smooth muscle deposition within vaginal mesh explants (SMA+ area fraction per high power field). (D) Quantification of CD31 and SMA co-distribution as measured by intensity correlation index. Wild type, non-operated vaginal tissue: n=2; surgical closure only: n=2; PEP with surgical closure: n=4; PEP injection only: n=5 for A, C, and D; n=7 for B.
[0018] [Figure 7] Study flow diagram. (A) To create the mesh denudation model, a 3 cm x 3 cm area of epithelial and fibromuscular tissue was denuded and a square polypropylene mesh was fixed. (B) Animals entered either the acute or subacute arm, where they underwent healing for 1 week (acute) or 8 weeks (chronic). Following this period, animals received a single injection of PEP once (acute-single PEP, subacute-single PEP) or once a week for 4 weeks (acute-weekly PEP). Sacrifice was performed 4 weeks after the first injection of PEP. Abbreviations: PEP, purified exosome product.
[0019] [Figure 8]Epithelial regeneration after PEP treatment for mesh exposure. (A) Representative hematoxylin and eosin (H&E) images of explanted mesh-vaginal complexes. # indicates holes formed by 80 μm thick mesh fibers. Cross-sectional images in the acute single group show two connecting fibers and therefore larger diameter holes. (B) Mean thickness of regenerated vaginal epithelium across various PEP treatment groups measured over 4 ± 1.4 cm of epithelium per explanted mesh. ANOVA p=0.2. (C) Representative immunofluorescence images of vaginal epithelium (cytokeratin, green) labeled with EdU (red) as a marker of cellular regeneration. (D) Quantification of total proliferation, epithelial proliferation, and non-epithelial proliferation cell density (EdU+ cells per area) measured over 1.6 ± 0.3 cm of epithelium per mesh. ANOVA for total proliferation (p=0.049), ANOVA for epithelial proliferation (p=0.046), ANOVA for non-epithelial (p=0.043). For B / D, *p<0.05, n=2 (acute-single PEP), n=4 (acute-weekly PEP), and n=6 (subacute-single PEP). Data reported as mean±SEM.
[0020] [Figure 9] Vascularization of regenerated tissue after various PEP treatments versus mesh exposure. (A) Representative immunofluorescence images of subepithelial vessels (CD31, red) with EdU (white) marking regenerative cells. (B) Quantification of capillary density reported as CD31+ lumen per area of subepithelium (8.5±1.2 mm2 per mesh). ANOVA for vessels (p=0.0069), ANOVA for EdU+ vessels (p=0.022); *p<0.05, **p<0.01, n=2 (acute-single PEP), n=4 (acute-weekly PEP), and n=6 (subacute-single PEP); data reported as mean±SEM. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] Surgical implantation of polypropylene mesh is a widely accepted and durable treatment for women experiencing, for example, stress urinary incontinence or pelvic organ prolapse. These procedures are often performed when behavioral / non-surgical measures are unsuccessful in eliminating symptoms. Although mesh implantation is an effective treatment, some women experience mesh exposure over time. Mesh exposure can occur along the suture line or any area overlying the implant. This is suspected to occur due to a combination of intraoperative hemostasis during incision and poor wound healing after surgery. Many factors may contribute to a woman's risk of mesh exposure, including the volume of the implanted mesh, nutritional status, menopausal status, and medical comorbidities such as diabetes, immunosuppression, and smoking. Persistent exposure of the mesh can cause dyspareunia, psychological distress, abnormal discharge, and predispose women to vaginal infections. Vaginal estrogen is often used as a non-surgical treatment for exposure, but there is no high-level data on efficacy, and many patients continue to require reoperation for epithelial reclosure or mesh excision. Reoperation is costly and resection can lead to recurrence of symptoms.
[0022] Although described herein in the context of treating mesh exposure, the compositions and methods described herein may be applicable in other contexts, such as during the initial implantation or removal of a surgical mesh. The compositions described herein may be administered and / or the methods described herein may be performed before the mesh implantation procedure, during the mesh implantation procedure, after the mesh implantation procedure but before any exposure or other complications, during the mesh removal procedure, immediately after the mesh removal procedure, or at some point after the mesh removal procedure as a treatment if mesh exposure occurs. In addition, although described herein in the context of an exemplary model of vaginal mesh exposure, it should be understood that the compositions and methods described herein may be applied to other procedures involving surgical mesh, such as, for example, hernia repair, treatment of stress urinary incontinence, uterine prolapse, or reinforcement of other damaged tissue.
[0023] Research in tissue regeneration has increasingly been directed toward investigating stem cell therapy. However, the success of therapy has been limited by the cost and heterogeneity of culture techniques and delivery methods. In contrast, exosome delivery platforms can deliver therapeutic nucleic acids (e.g., miRNA), signaling proteins, and other regenerative substrates to activate endocrine, paracrine, and / or anti-inflammatory pathways. Exosomes can drive local stem cell activation and proliferation, eliminating the need for cell-based modalities.
[0024] The present disclosure describes therapeutic compositions comprising purified exosome products (PEP). These compositions can be used in methods for treating vaginal mesh exposure. PEP is a purified exosome product prepared using a freeze-drying process that produces a product with a structure and composition different from exosomes prepared using conventional methods. PEP is stable at room temperature and can be reconstituted in a pharmaceutical carrier (e.g., pH-neutralized collagen-1) to create an injectable composition for the non-surgical management of inadequate vaginal tissue healing, as described in more detail below.
[0025] The production of purified exosome product (PEP) involves separating plasma from blood and isolating a solution of exosomes from the separated plasma by filtration and centrifugation. PEP is fully characterized and methods of preparation of PEP are described in International Patent Application No. PCT / US2018 / 065627 (published as International Publication No. WO2019 / 118817), U.S. Patent Publication No. 2021 / 0169812A1, and U.S. Patent No. 10,596,123, each of which is incorporated herein by reference in its entirety. Briefly, PEP is a purified exosome product prepared using a freeze-drying process that produces a product with a different structure than exosomes prepared using conventional methods. For example, PEP typically has a spherical or spheroidal structure and an intact lipid bilayer, rather than the crystalline structure that results from lipid reaggregation of the exosome lipid bilayer after exosomes are disrupted during conventional exosome preparation methods. The spherical or spheroidal exosome structure generally has a diameter of 300 nm or less. Typically, PEP preparations contain spherical or spheroidal exosome structures with a relatively narrow size distribution. In some preparations, PEP contains spherical or spheroidal exosome structures with a mean diameter of about 110 nm ± 90 nm, and the majority of exosome structures have a mean diameter of 110 nm ± 50 nm, such as 110 nm ± 30 nm.
[0026] Unmodified PEP preparations, i.e., PEP preparations whose characteristics have not been altered by sorting or separation of the exosome population in the preparation, exhibited CD63 + Exosomes and CD63 - Naturally contains exosomes. CD63 - Exosomes can inhibit unlimited cell proliferation, and thus CD63 + and CD63 - Unmodified PEP preparations naturally comprising exosomes can stimulate cell proliferation for wound repair and / or tissue regeneration or limit uncontrolled cell proliferation.
[0027] In addition, CD63+ CD63 from naturally isolated PEP preparations by exosome sorting + The exosomes are then extracted with the desired amount of CD63 + By adding back exosomes, CD63 in the PEP product - CD63 on exosomes + In one or more embodiments, the PEP preparation comprises a CD63 exosome. - It may have only exosomes.
[0028] In one or more embodiments, the PEP preparation comprises CD63 + Exosomes and CD63 - Exosomes may contain both CD63 and CD63. + Exosomal CD63 - The ratio of CD63 to exosomes may vary, at least in part, depending on the amount of cell proliferation desired in a particular application. + / CD63 - Exosome ratio is CD63 + Desired cell proliferation induced by exosomes and CD63 achieved through cell contact inhibition - In certain scenarios, such as tissues with non-adherent cells (e.g., blood-derived components), this ratio can be adjusted to provide the appropriate balance of cell proliferation or cell inhibition for the tissue being treated. For example, in tissues with non-adherent cells, cell-to-cell contact is not a trigger, so CD63 + Conversely, if one wishes to expand a clonal population of cells, such as in allogeneic cell-based therapies or immunotherapy, one may wish to use CD63 to ensure that a large cell population can be obtained from a very small source. + The ratio of exosomes can be increased.
[0029] Thus, in one or more embodiments, CD63 in the PEP preparation + Exosomes and CD63- The ratio of CD63 in the PEP preparation to exosomes can be at least 1:1, at least 2:1, at least 3:1, at least 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1, at least 9:1, at least 10:1, at least 11:1, at least 12:1, at least 13:1, at least 14:1, at least 15:1, or at least 16:1. + Exosomes and CD63 - The ratio of CD63 to exosomes can be up to 15:1, up to 16:1, up to 17:1, up to 18:1, up to 19:1, up to 20:1, up to 25:1, or up to 30:1. + Exosomes and CD63 - The ratio of exosomes can be 1:1 to 30:1, 2:1 to 20:1, 4:1 to 15:1, or 8:1 to 10:1. In one or more specific embodiments, the PEP product contains a 9:1 ratio of CD63 + Exosomes vs. CD63 - In one or more particular embodiments, the exosome is formulated to contain a natural PEP, such as CD63. + Exosomes and CD63 - An unaltered ratio of PEP to exosomes may also be used.
[0030] The present disclosure describes the use of PEP as an adjunct to surgical intervention or as a stand-alone therapy to treat surgical mesh (e.g., vaginal mesh) exposure. The addition of PEP to standard surgical reclosure results in improved resolution of mesh exposure in a porcine model, e.g., tissue healing and reclosure. The described porcine model is a valid indicator of clinical utility for use in various situations of surgical mesh exposure in general, and in subjects of other species, including humans. Furthermore, PEP can independently achieve resolution of mesh exposure without further surgical intervention in exposures of clinically meaningful size (e.g., greater than 1×1 cm). Consistent with the tenets of regenerative medicine (regeneration of functional tissue), PEP-treated tissues demonstrate superior vascularization, epithelial thickness, viscoelasticity, and inflammatory profiles over non-PEP-treated exposures.
[0031] Although exemplified below in the context of an exemplary model in which the subject is a pig, the compositions and methods described herein may include any suitable subject. As used herein, a "subject" may be a human or any non-human mammal. Exemplary non-human animal subjects include, but are not limited to, livestock animals or companion animals. Exemplary non-human animal subjects include, but are not limited to, members of the family Hominidae (including, for example, chimpanzees, gorillas, or orangutans), subfamily Bovinae (including, for example, cattle), subfamily Caprinae (including, for example, goats), genus Ovis (including, for example, sheep), porcinae (including, for example, pigs), family Equidae (including, for example, horses), members of the family Cervidae (including, for example, deer, elk, moose, caribou, reindeer, etc.), members of the family Bisonidae (including, for example, bison), family Felidae (including, for example, domestic cats, tigers, lions, etc.), family Canidae (including, for example, domestic dogs, wolves, etc.), birds (including, for example, turkeys, chickens, ducks, geese, etc.), rodents (including, for example, mice, rats, etc.), members of the family Leporidae (including, for example, rabbits or hares), members of the family Mustelidae (including, for example, ferrets), or members of the order Chiroptera (including, for example, bats):
[0032] Also, although described below in the context of an exemplary embodiment involving vaginal epithelium damaged as a result of mesh exposure, the compositions and methods described herein may include treatment of any tissue, and thus any epithelial tissue damaged as a result of mesh exposure.
[0033] Surgical mesh exposure model All animals completed the study without adverse events. The described mesh exposure model proved appropriate to study implants of clinically meaningful size. Pigs weighing 70-80 kg allowed for adequate vaginal diameter and depth for implanting multiple meshes as well as the use of standard surgical instruments. All meshes were retained by fixation with 2-0 polypropylene. One animal in the PEP-only group experienced "ballooning" of the central portion of the mesh implant but still demonstrated re-epithelialization underneath the mesh (confirmed histologically).
[0034] Macroscopic analysis of the vagina / mesh complex Figure 2A shows macroscopic examination of the explanted vagina-mesh complex. Tissues treated with PEP and concomitant surgical closure (Group 1B) demonstrated the most significant resolution of mesh exposure, followed by the PEP alone (Group 2) and then the surgical closure alone group (Group 1A).
[0035] Among groups treated with surgical closure, the addition of PEP reduced the incidence of wound dehiscence (e.g., separation of tissue around the injury) compared to closure alone. All four of the mesh with closure only (Group 1A) had mesh dehiscence and re-exposure. The four PEP + closure mesh exposures (Group 1B) demonstrated resolution of mesh exposure of 50-95%.
[0036] Animals treated with PEP only (Group 2) demonstrated robust vaginal regeneration despite the lack of surgical closure. One animal had ballooning of the mesh complex as previously described. Therefore, no mention can be made of overall resolution of mesh exposure. On histology, tissue samples beneath the ballooned mesh demonstrated the presence of regenerated tissue in the center of the previously denuded area. The remaining animals in the PEP only group demonstrated regeneration of vaginal tissue over the 1 centimeter (cm), 2 cm, and 3 cm implants, with the largest implant demonstrating near-complete resolution of exposure (Figure 2A).
[0037] Histological analysis of regenerated tissue PEP-treated vagina-mesh complexes with or without surgical closure showed re-establishment of the basement membrane (Fig. 2B) and intact epithelium similar to uninjured wild-type vaginal tissue (Fig. 2A). In contrast, atresia-only tissues showed frequent disruption and cellular disarray in the epithelium (Fig. 2A; Fig. 3A,B). TEM analysis confirmed the presence of basement membrane and round cells that maintained cellular junctions in the PEP+atresia group, in contrast to poorly regenerated basement membrane and scar formation in the atresia-only group (Fig. 2B). Histological specimens were reviewed by an independent blinded pathologist, corroborating the findings presented herein. Hematoxylin and eosin (H&E) stained sections revealed increased epithelial thickness in PEP+atresia (217 μm) and PEP-only (208 μm) samples compared to controls (80 μm, p=0.03; Fig. 3A, Fig. 4A). Immunohistochemical analysis of PEP-treated tissues demonstrated appropriate expression of epithelial markers pan-cytokeratin (Fig. 3B,C), submucosal collagen III (Fig. 3B), and E-cadherin (Fig. 5A), similar to wild-type tissue.
[0038] In one or more embodiments, the methods and compositions described herein may reduce the formation of scar tissue in or around a surgical mesh. Scar tissue formation may be measured, for example, by microscopic visualization of flattened, disorganized epithelial cells. Compared to the uniform tissue structure and complete coverage in the PEP-treated groups ("PEP+Occlusion" and "PEP Only" in FIG. 2A), heterogeneous scar tissue formation can be visually observed at the mesh implantation site, where partial mesh morphology is still present ("Occlusion Only" in FIG. 2A). Histologically, abnormal morphology of the epithelial layer can be recognized in the "Occlusion Only" group (FIG. 2B) compared to the wild-type untreated control group. PEP treatment restored the uniform tissue structure and cellular organization observed in the wild-type (FIG. 2B).
[0039] Assessment of proliferation and inflammation in regenerated tissue The basal cell layer of the squamous epithelium in the vagina is responsible for proliferation. Thus, proliferation is related to the Ki67 per length of epithelium. + Compared to uninjured wild-type vaginal tissue, all experimental animals showed a trend toward higher rates of total and epithelial proliferation (Figure 3C; Figure 4B), with high densities of Ki67 cells. + Cells line the basal layer of the epithelium. To ensure that the restored epithelium was derived from new cells, 2'-deoxy-5-ethynyluridine (EdU) patterns were assessed. In the PEP-only group, EdU was present throughout the epithelium and underlying tissue, confirming de novo regeneration over the study period (Figure 4C). Atresia-only vaginal / mesh complexes tended to have higher proliferation in the non-epithelial submucosal compartment (Figure 4B), suggesting infiltration of rapidly proliferating fibroblasts and / or inflammatory cells. Analysis of CD3 expression showed the highest tendency toward T-cell infiltration, indicative of chronic inflammation, in the atresia-only subgroup (Figure 5A; Figure 6A).
[0040] Angiogenesis and fibrosis in the vagina / mesh complex CD31 + Analysis of endothelial cell presence via expression demonstrated a higher capillary density in the PEP+Occlusion group compared to wild-type tissue (185 vessels / mm2 vs. 85 vessels / mm 2 , p=0.03; FIG. 4B; FIG. 6B). Interestingly, occlusion only tissues showed increased expression of smooth muscle actin (SMA), due in part to excess interstitial smooth muscle deposition (FIG. 6C). Tissues treated with PEP showed increased SMA expression compared to uninjured tissue, but decreased SMA expression compared to occlusion only tissue. Analysis of the co-distribution of SMA and CD31 demonstrated the highest intensity correlation index (ICQ) in uninjured wild-type tissue, the lowest in the occlusion only group, and intermediate in PEP-treated tissue (FIG. 6D), confirming interstitial smooth muscle deposition in the occlusion only cohort.
[0041] The above studies establish the utility of PEP injections to resolve acute (e.g., 1 week after birth) vaginal mesh exposure in a porcine model of mesh exposure. In the studies described below, the effect of remedying (single dose regimen vs. multiple dose regimen) on wound healing in a mesh exposure model. Specifically, epithelial thickness, regenerative cell population, and vascularization were evaluated. The multiple dose regimen shows the highest regenerative profile. Resolution of mesh exposure was compared with surgical intervention, surgical intervention with simultaneous PEP injection, and PEP injection alone. In brief, PEP alone variably treated mesh exposures up to 3 cm x 3 cm in size. PEP-treated tissues had a thicker regenerative epithelium and a lower fibrosis and inflammatory profile compared to surgical management alone.
[0042] All on-protocol animals completed the study without adverse events. Systematic multi-organ on- and off-target necropsy evaluations were performed with no relevant findings. Safety evaluations also included multi-organ histological evaluations, periodic vital signs, and blood tests. Results were analyzed in aggregate across all three groups using one-way ANOVA followed by pairwise comparisons with post-hoc Tukey's test. Results are presented evaluating (1) single vs. multiple dose protocols, and (2) acute vs. subacute mesh exposure (e.g., Figures 4, 6, 8, and 9).
[0043] In one or more embodiments, the methods and compositions described herein may improve the resolution of surgical mesh exposure as measured by any suitable histological measurement. For example, the methods and compositions described herein may increase angiogenesis, decrease fibrosis, decrease inflammatory profiles, increase epithelial thickness, increase cell proliferation, and / or increase expression of markers of tissue repair such as e-cadherin, cytokeratin, and collagen.
[0044] Single-dose versus multiple-dose PEP regimens in acute mesh exposure Evaluation of hematoxylin and eosin (H&E) stained sections revealed increased epithelial thickness (single PEP 175.4 μm, weekly PEP 259 μm, ANOVA p=0.2, not statistically significant) and qualitatively less epithelial disruption in the weekly PEP group compared to the single PEP group (Figure 8A,B). Mesh fibers were found to be well integrated into the subepithelial fibromuscular tissue in both groups. The weekly PEP group showed fewer perifibrous nucleated cells.
[0045] Animals were administered EdU twice weekly after the first PEP injection and then tissue regeneration was followed after the intervention. Regeneration was reported for the total (epithelial and non-epithelial) cell population, the epithelial cell population, and the non-epithelial cell population (reported as density). Total cell proliferation was significantly different between all groups (ANOVA p=0.049, FIG. 8D). There was a trend towards higher total proliferation when comparing the acute-weekly PEP group to the group receiving a single PEP injection, but this was not significant in post-hoc analysis (p=0.216). Epithelial proliferation was almost two-fold higher in the acute weekly PEP group versus the acute single PEP group (1011 vs. 556 EdU + cells / mm 2 , p=0.038). This indicates that the multiple-dose regimen contributes to a higher rate of epithelial proliferation, which is further supported by the increased epithelial thickness, even though the difference in epithelial thickness did not reach statistical significance.
[0046] CD31 + Analysis of endothelial cell presence using expression showed a significant difference in capillary density between groups (ANOVA p=0.007, FIG. 9B). Post-hoc analysis of capillary density between single and multiple doses was not significant (p=0.316). + / CD31 + Vascular lumen / mm 2 When assessing regenerated capillary density as measured by , there was a significant difference in regenerated capillary density between groups (ANOVA p=0.022), with the weekly PEP group having a higher regenerated capillary density compared to the single PEP group (p=0.030).
[0047] Treatment of acute versus subacute mesh exposure with a single PEP injection The subacute exposure group showed less disruption in the epithelium in hematoxylin and eosin (H&E) stained sections (Figure 8A). Of note, mesh fibers were well integrated in the subepithelial space with fewer surrounding nucleated cells in the subacute vs. acute groups, possibly indicating a reduction in acute phase inflammatory cells over time. When compared across acute and subacute mesh exposure groups, epithelial thickness was similar (acute 175 μm vs. subacute 203 μm, p=0.828; Figure 8B).
[0048] The total cell proliferation between the acute and subacute groups was not statistically different (p=0.943). However, the subacute group showed higher epithelial proliferation compared to the acute group (subacute 914 vs. acute 556 EdU). + cells / mm 2 , p = 0.081, not statistically significant; Figure 8D), and the ratio of epithelial to non-epithelial proliferation was higher (subacute 1.5 vs. acute 0.6). This trend is visually demonstrated in Figure 8C, where EdU is enriched in cytokeratin-positive epithelium.
[0049] Capillary density did not differ between the acute and subacute mesh exposure groups (p=0.253; Figure 9B). Regenerated capillary density in the single-dose acute group was similar to the subacute group (p=0.526). Of note, the vascular lumen in the subacute group appeared larger (Figure 9A), indicating natural vascular adhesion with healing, which partially explains the trend for reduced capillary density. Furthermore, EdU, but not density, + When comparing the vascular fraction, the subacute group had 25% EdU compared with 19% in the acute group. + This further corroborates the fact that although the vascular lumen density was lower, both the absolute number and size of regenerating vessels were higher in the subacute group.
[0050] In this preclinical large animal study using an injectable exosome regeneration platform (PEP) in a vaginal mesh denudation model, a multiple dose regimen was found to be superior to a single dose regimen, with PEP exosomes being effective in both acutely and subacutely denuded meshes. These findings add to the data establishing the effectiveness of PEP as a non-surgical treatment for vaginal mesh denudation. Specifically, this study established the pattern of regenerated vaginal tissue and blood vessels with the use of EdU. Exosomes typically deliver a host of growth factors, antioxidants, microRNAs, and endocrine / paracrine signals to stimulate localized regeneration. Dose-dependent EdU + The data herein showing angiogenesis and epithelial proliferation provide further evidence for this mechanism.
[0051] Factors including menopausal status, nutritional status, medical comorbidities such as diabetes mellitus and immunosuppression, and smoking contribute to vaginal mesh exposure. A commonality between these factors is their effect on wound healing. The regenerative properties of PEP exosomes were evaluated to address vaginal mesh exposure.
[0052] PEP improves vaginal tissue regeneration after mesh exposure to an extent that suggests surgery may not be necessary or may be used as a second-line treatment for mesh exposure (Figures 1-6). Furthermore, the effect of re-dosing and timing of PEP administration was evaluated. The regenerated epithelium (thickness and EdU + The tissue regeneration rate was evaluated by measuring the vascular endothelial cell density and the vascular endothelial cell density.
[0053] Epithelial regeneration was used as a measurable marker of vaginal tissue regeneration, given that epithelium and fibromuscular tissue were denuded in the creation of the model. There was a significant increase in epithelial thickness with repeated administration. Even a single injection on a delayed schedule resulted in beneficial regrowth of the epithelium. Epithelial regeneration (EdU + epithelial cells / mm 2) was statistically higher using the multiple-dose regimen, suggesting a positive dose-response effect. Indeed, epithelial regeneration was higher in the single-dose subacute group compared to the acute group, accompanied by a relative decrease in the proliferative fraction within the subepithelial layer, which may be due to the capillary coalescence pattern discussed below.
[0054] Regenerative capillary density was higher using the multiple-dose protocol but was still similar between single-dose acute and subacute mesh exposures. The maturation phase of angiogenesis extends beyond 2-4 weeks after injury. Thus, the increased number of well-formed lumens at 4 weeks after PEP injection suggests improved physiological angiogenesis. Looking at the pattern and distribution of blood vessels on immunohistochemistry (Figure 9A), the acute group has a greater number of small capillaries, contrasting with fewer but larger vessels in the subacute group. This pattern of small capillaries coalescing to form mature vessels is well described in the wound healing literature. The observed vascular maturation drives on-target proliferation as seen in the ratio of epithelial / non-epithelial proliferation in this study.
[0055] This disclosure presents data from a porcine mesh inlay model that supports the use of a novel exosome therapy, PEP, for surgical mesh (e.g., vaginal mesh) exposure. Thus, PEP can serve as a non-surgical, cost-saving solution to mesh exposure. PEP is shelf stable and easy to inject, making it accessible to clinicians in urban and rural practice, as well as for improving global health. This therapy avoids the issues related to cell culture and cell delivery heterogeneity associated with stem cells. The data presented herein demonstrates the benefits of remedying.
[0056] Thus, the present disclosure describes a model animal study using an injectable acellular regenerative platform for mesh exposure. PEP injection with surgical intervention resulted in robust vaginal tissue regeneration and resolution of mesh exposure compared to surgical intervention alone, all of which experienced mesh dehiscence / reexposure. Exposures treated with PEP alone (without surgical intervention) showed variable mesh exposure resolution, with resolution achieved up to a size of 3×3 cm. The regenerated tissues established proper microanatomy as demonstrated by TEM and light microscopy. Furthermore, PEP-treated tissues showed lower fibroblast proliferation and inflammation. These findings reveal the regenerative, anti-inflammatory, and angiogenic capabilities of PEP. Overall, tissues treated with PEP demonstrated thicker regenerated epithelium with reduced fibrosis and inflammatory profiles compared to the closure-only group. Furthermore, multiple dosing regimens have been shown to further increase the effect of PEP administration on exposed mesh resolution.
[0057] Importantly, the data reported herein complement existing data on chronic non-healing wounds and, more specifically, on the host response to mesh implantation and the drivers of mesh complications. Mesh / vaginal complexes in women undergoing surgery for mesh complications may contain exposed tissues with exaggerated M2 macrophage and matrix metalloproteinase-9 (MMP) responses and relative increases in T cell populations indicative of fibrosis and degradation. In non-human primate models, heavier, less porous, stiffer meshes had deleterious effects on the extracellular matrix, resulting in increased MMPs and collagen and elastin catabolism. Inadequate host regenerative efforts (e.g., chronic inflammation, ECM remodeling) contribute to mesh exposure and subsequent failure of surgical management of mesh exposure. Thus, using PEP to reduce inflammation and promote controlled regeneration may reduce the risk of mesh exposure and promote healing in the setting of existing exposure.
[0058] The data presented herein demonstrate that exosome therapy, such as PEP, shows promise in vaginal tissue regeneration. Exosome-treated vaginal mesh exposure demonstrated robust vaginal tissue regeneration, resulting in partial to complete resolution of exposure. Application of this platform may result in a paradigm shift in how urologists approach mesh complications.
[0059] Thus, the present disclosure describes compositions and methods for improving the repair of mesh exposure.Generally, the compositions include PEP and a pharma- ceutically acceptable carrier.In a surgical setting, the PEP may be combined with a carrier (e.g., a surgical adhesive or tissue adhesive) suitable for application to surgically repaired tissue.
[0060] Thus, the method includes administering an effective amount of the composition to a tissue in need of repair after exposure of the surgically implanted mesh. As used herein, tissue in need of repair can refer to tissue adjacent to the surgical mesh, such as, for example, degenerated vaginal epithelium and / or vaginal epithelial tissue in direct contact with the vaginal mesh. Administering the composition to a tissue in need of repair can also include administering the composition to intact or healthy tissue in sufficient proximity to the damaged tissue such that administration at the intact or healthy site promotes healing of the nearby damaged tissue, for example, without further disrupting the damaged tissue with the needle used to deliver the composition. For example, the PEP composition can be administered by injection into healthy tissue that is up to 25 cm (e.g., 1 cm, 2 cm, 3 cm, 4 cm, 5 cm, 10 cm, 20 cm, etc.) from the damaged tissue.
[0061] In this embodiment, an "effective amount" is an amount effective to increase epithelial thickness, epithelial cell proliferation, and / or vascularization (e.g., capillary density) compared to untreated epithelial tissue or epithelial tissue treated with carrier alone (without PEP).
[0062] PEP can be formulated with a pharma- ceutically acceptable carrier to form a pharmaceutical composition. As used herein, "carrier" includes any solvent, dispersion medium, vehicle, coating agent, diluent, antibacterial and / or antifungal agent, isotonic agent, absorption delaying agent, buffer, hydrogel, carrier solution, suspension, colloid, and the like. The use of such media and / or agents for pharma- ceutical active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic composition is contemplated. Supplementary active ingredients can also be incorporated within the composition. As used herein, "pharma- ceutical acceptable" refers to a substance that is not biologically or otherwise undesirable, i.e., the substance can be administered to an individual together with PEP without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is included. As mentioned above, in a surgical setting, exemplary suitable carriers include surgical adhesives, tissue adhesives, or support matrices (e.g., collagen scaffolds).
[0063] In one or more embodiments, the PEP composition may include additional components, either mixed with the PEP vesicles or loaded into at least a portion of the PEP vesicles. In one or more embodiments, the additional components may promote healing. In one or more embodiments, the additional components may include one or more biocompatible scaffold components, such as, for example, collagen, fibrin, fibronectin, laminin, proteoglycan, hyaluronic acid, alginate, or other biocompatible scaffold components. In one or more embodiments, the additional components may include one or more pharma- ceutically active components. In one or more embodiments, the pharma-ceutically active components may be selected, for example, to reduce healing time, to provide pain relief, or to reduce the likelihood or severity of complications (e.g., infection). The pharma-ceutically active components may include, for example, steroids (e.g., estrogen), painkillers, or antibiotics. One or more of the additional components may be loaded into at least a portion of the PEP vesicles. The presence of a particular component in a PEP preparation can be, for example, the result of expression of the component (e.g., a protein) by the donor cell from which the PEP is derived. Additionally or alternatively, one or more components may be loaded into at least a portion of the PEP vesicles, either directly (loading of the component itself) or indirectly (e.g., a recombinantly expressed protein).
[0064] In one or more embodiments in which the composition includes collagen, the collagen may be provided as a fibrillar collagen, such as procollagen, type I collagen, type III collagen, or a combination thereof. In embodiments in which the composition includes collagen, the collagen may be provided as a collagen scaffold. In one or more other embodiments, the extracellular matrix component may be provided in any suitable form, such as purified recombinant protein. In one or more embodiments, the composition may include PEP and one or more support matrix components (e.g., collagen) in a ratio of 1:20 to 1:5 (5% v / v to 20% v / v). In one or more alternative embodiments, the ratio of PEP to support matrix components may be 1:100, 1:500, 1:1000, 1:10, 1:5, 1:2, or 1:1 by volume. Any medically suitable form of collagen may be included in the composition, such as, for example, type I collagen, type II collagen, or type III collagen. The collagen may be derived from a mammalian source, such as a bovine or human source. The collagen fibril structure can be native, atelocollagen, hydrolyzed, or a combination of several types. Typically, using gel electrophoresis, no more than 10% of the collagen in the collagen scaffold exhibits faster migration characteristics than alpha.
[0065] Pharmaceutical compositions containing PEP can be formulated in a variety of forms suitable for the preferred route of administration. Thus, pharmaceutical compositions can be administered via known routes, including, for example, orally, parenterally (e.g., intradermally, transdermally, subcutaneously, intramuscularly, intravenously, intraperitoneally, submucosally, etc.), or topically (e.g., application to exposed nerve tissue during surgery, intranasally, intrapulmonary, intramammary, intravaginally, intrauterine, intradermally, transdermally, rectally, etc.). Pharmaceutical compositions can be administered to mucosal surfaces, such as, for example, by administration to the nasal or respiratory mucosa (e.g., by spray or aerosol). Pharmaceutical compositions may also be administered via sustained or delayed release. Pharmaceutical compositions can be administered, for example, in the form of one or more injections, suppositories, topical gels, patches, or non-surgical implants, such as rings. Pharmaceutical compositions can be administered embedded in physical scaffolds, such as bandages, sutures, staples, splints, or surgical meshes. In one or more embodiments, multiple administration methods may be utilized during a single procedure.
[0066] Thus, the pharmaceutical composition may be provided in any suitable form, including but not limited to the form of a solution, suspension, emulsion, spray, aerosol, or any mixture.The pharmaceutical composition may be provided in a formulation that includes any pharma- ceutically acceptable excipient, carrier, or vehicle.For example, the formulation may be provided in a conventional topical dosage form, such as, for example, cream, ointment, aerosol formulation, suppository, non-aerosol spray, gel, lotion, etc.The formulation may further include one or more additives, including, for example, adjuvants, skin penetration enhancers, colorants, fragrances, flavorings, moisturizers, thickeners, etc.
[0067] The formulation may be provided in a convenient unit dosage form and can be prepared by a method known in the art of pharmacy.The method of preparing the composition containing a pharmaceutically acceptable carrier comprises the step of associating PEP with a carrier which constitutes one or more accessory ingredients.In general, the formulation can be prepared by uniformly and / or intimately associating PEP with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into desired formulation.
[0068] The amount of PEP administered may vary depending on various factors, including but not limited to the content and / or source of the PEP administered, the weight, health condition, and / or age of the subject, and / or the route of administration. Thus, the absolute weight of PEP contained in a given unit dosage form may vary widely and depends on factors such as the species, age, weight, and health condition of the subject, and / or the method of administration. Therefore, it is not practical to generally state the amount that constitutes the amount of PEP that is effective for all possible uses. However, those skilled in the art can easily determine the appropriate amount by fully considering such factors.
[0069] In one or more embodiments, the dose of PEP can be measured in terms of the dose of PEP exosomes delivered. Thus, in one or more embodiments, the method can include administering, for example, about 1×10 6 PEP exosomes ~ approx. 1 × 10 15 This may include administering sufficient PEP to provide a dose of PEP exosomes to the subject, although in one or more embodiments the method may be carried out by administering PEP at a dose outside this range.
[0070] Thus, in one or more embodiments, the method comprises: 6 PEP exosomes, at least 1 × 10 7 PEP exosomes, at least 1 × 10 8 PEP exosomes, at least 1 × 10 9 PEP exosomes, at least 1 × 10 10 PEP exosomes, at least 1 × 10 11 PEP exosomes, at least 2 × 10 11 PEP exosomes, at least 3 × 10 11 PEP exosomes, at least 4 × 10 11 PEP exosomes, at least 5 × 10 11 PEP exosomes, at least 6 × 10 11 PEP exosomes, at least 7 × 10 11 PEP exosomes, at least 8 × 1011 PEP exosomes, at least 9 × 10 11 PEP exosomes, at least 1 × 10 12 PEP exosomes, 2 × 10 12 PEP exosomes, at least 3 × 10 12 PEP exosomes, at least 4 × 10 12 PEP exosomes, or at least 5 × 10 12 PEP exosomes, at least 1 × 10 13 PEP exosomes, or at least 1 × 10 14 This may include administering sufficient PEP to provide a minimum dose of the PEP exosomes.
[0071] In one or more embodiments, the method comprises: 15 PEP exosomes, 1 × 10 14 PEP exosomes, 1 × 10 13 PEP exosomes, 1 × 10 12 PEP exosomes, 1 × 10 11 or 1×10 10 This may include administering sufficient PEP to provide a maximum dose of PEP exosomes of:
[0072] In one or more embodiments, the method may include administering sufficient PEP to provide a dose characterized by a range having endpoints defined by any minimum dose identified above and any maximum dose greater than the minimum dose. For example, in one or more embodiments, the method may include administering a dose of PEP of, for example, 1×10 11 ~5×10 12 Dose of PEP exosomes, 1 × 10 12 ~1×10 13 Dose of PEP exosomes, or 5 × 10 12 ~1×10 13 Dose of PEP exosomes e.g. 1 x 10 11 ~1×10 13The method may include administering sufficient PEP to provide a dose of PEP exosomes. In one or more particular embodiments, the method may include administering sufficient PEP to provide a dose equal to any minimum dose or any maximum dose listed above. Thus, for example, the method may include administering a 1×10 10 PEP exosomes, 1 × 10 11 PEP exosomes, 5 × 10 11 PEP exosomes, 1 × 10 12 PEP exosomes, 5 × 10 12 PEP exosomes, 1 × 10 13 PEP exosomes, or 1 × 10 14 This may involve administering a dose of PEP exosomes.
[0073] Alternatively, the dose of PEP can be measured in terms of the concentration of PEP upon reconstitution from a lyophilized state. Thus, in one or more embodiments, the method can include administering PEP to a subject at a dose of, for example, about a 0.01% solution to a 100% solution, although in one or more embodiments, the method can be practiced by administering PEP at a dose outside of this range. As used herein, a 100% solution of PEP refers to a concentration of PEP (about 2×10 11 The dose of 0.01% PEP refers to one vial of exosomes (75 mg or 100 mg). For comparison, the dose of 0.01% PEP is approximately equivalent to a standard dose of exosomes prepared using conventional methods of obtaining exosomes, such as exosome isolation from cells in vitro using standard cell conditioned media.
[0074] Thus, in one or more embodiments, the methods may include administering sufficient PEP to provide a minimum dose of at least 0.01%, at least 0.05%, at least 0.1%, at least 0.25%, at least 0.5%, at least 1.0%, at least 2.0%, at least 3.0%, at least 4.0%, at least 5.0%, at least 6.0%, at least 7.0%, at least 8.0%, at least 9.0%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, or at least 70%.
[0075] In one or more embodiments, the methods may include administering sufficient PEP to provide a maximum dose of 100% or less, 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, 9.0% or less, 8.0% or less, 7.0% or less, 6.0% or less, 5.0% or less, 4.0% or less, 3.0% or less, 2.0% or less, 1.0% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, or 0.1% or less.
[0076] In one or more embodiments, the method may include administering sufficient PEP to provide a dose characterized by a range having endpoints defined by any minimum dose identified above and any maximum dose greater than the minimum dose. For example, in one or more embodiments, the method may include administering sufficient PEP to provide a dose between 1% and 50% of the dose, e.g., between 5% and 20% of the dose. In one or more particular embodiments, the method may include administering sufficient PEP to provide a dose equal to any minimum dose or any maximum dose listed above. Thus, for example, the method may include administering a dose of 0.05%, 0.25%, 1.0%, 2.0%, 5.0%, 20%, 25%, 50%, 80%, or 100%.
[0077] A single dose may be administered all at once, continuously over a prescribed time, or in multiple separate doses. When multiple doses are used, each dose may be the same or different. For example, a prescribed daily dose may be administered as a single dose, or as two equal or unequal doses continuously over a 24-hour period. When multiple doses are used to deliver a single dose, the interval between doses may be the same or different. In certain embodiments, PEP may be administered as a one-off dose, for example, during a surgical procedure.
[0078] In certain embodiments in which multiple doses of the PEP composition are administered to the subject, the PEP composition may be administered as needed to treat the damaged vaginal tissue to the desired extent. Alternatively, the PEP composition may be administered 2, 3, 4, 5, 6, 7, 8, 9, or at least 10 times. The interval between doses may be at least one day, such as at least 3 days, at least 5 days, at least 7 days, at least 10 days, at least 14 days, or at least 21 days. The interval between doses may be at most 6 months or less, such as 3 months or less, 2 months or less, 1 month or less, 21 days or less, or 14 days or less.
[0079] In one or more embodiments, the method may include multiple administrations of PEP to a subject at intervals (in the case of two administrations) or multiple intervals (in the case of three or more administrations) characterized by a range having endpoints defined by any minimum interval and any maximum interval greater than the minimum interval identified above. For example, in one or more embodiments, the method may include multiple administrations of PEP at intervals of 1 day to 6 months, such as 3 days to 10 days. In certain embodiments, the method may include multiple administrations of PEP at intervals equal to any minimum interval or any maximum interval listed above. Thus, for example, the method may include multiple administrations of PEP at intervals of 3 days, 5 days, 7 days, 10 days, 14 days, 21 days, 1 month, 2 months, 3 months, or 6 months.
[0080] In one or more embodiments, the methods may include administering a cocktail of PEPs prepared from a variety of cell types, where each cell type has a unique epithelial growth profile, e.g., protein composition and / or gene expression, etc. In this manner, the PEP composition can provide a broader spectrum of epithelial tissue growth promoting activity than if the PEP composition were prepared from a single cell type.
[0081] In the foregoing description and in the claims that follow, the term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements; the terms "comprise", "comprising" and variations thereof are to be construed as open-ended, i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, "a", "an", "the", and "at least one" are used interchangeably to mean one or more; and the recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
[0082] Throughout this specification, references to "one embodiment," "an embodiment," "a particular embodiment," "some embodiments," or "one or more embodiments" mean that a particular feature, configuration, composition, or characteristic described in connection with an embodiment is included in at least one embodiment of the present disclosure. Thus, the appearance of such phrases in various places throughout this specification does not necessarily refer to the same embodiment of the present disclosure. Furthermore, certain embodiments may be described alone for clarity. Thus, unless a feature of a particular embodiment is expressly specified as being incompatible with a feature of another embodiment, a particular feature, configuration, composition, or characteristic may be combined in any suitable manner in one or more embodiments. Thus, a feature described in the context of one embodiment may be combined with a feature described in the context of a different embodiment, unless the features are necessarily mutually exclusive.
[0083] The words "preferred" and "preferably" refer to embodiments of the invention that may provide certain benefits, under particular circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention.
[0084] In any method disclosed herein that includes separate steps, the steps may be performed in any practicable order, and, if desired, any combination of two or more steps may be performed simultaneously.
[0085] Exemplary embodiments Embodiment 1 is a method for treating surgical mesh exposure in a subject, comprising: The method includes administering PEP to tissue adjacent to the area of exposed surgical mesh in an amount effective to treat the area of exposed surgical mesh.
[0086] Embodiment 2 is a method for treating surgical mesh exposure in a subject, comprising: surgically closing the area of exposed surgical mesh; administering PEP to the epithelium adjacent to the surgical closure in an amount effective to treat the area of exposed surgical mesh.
[0087] Embodiment 3 is a method according to embodiment 1 or embodiment 2, wherein the amount effective to treat the area of exposed surgical mesh comprises an amount effective to increase epithelial proliferation to reduce the area of exposed surgical mesh, to increase the thickness of the epithelium overlying the surgical mesh, or to increase vascularization of the epithelium overlying the surgical mesh.
[0088] Embodiment 4 is the method of any one of embodiments 1 to 3, wherein the PEP is administered once.
[0089] Embodiment 5 is the method of any one of embodiments 1-3, wherein PEP is administered two or more times.
[0090] Embodiment 6 is the method of embodiment 5, wherein the PEP is provided in 2-4 doses.
[0091] Embodiment 7 is the method of embodiment 5 or embodiment 6, wherein the PEP is administered with an interval of about 7 days between administrations.
[0092] In an eighth embodiment, the PEP is at least 10 12 10. The method according to any one of embodiments 1 to 9, wherein the PEP exosomes are administered in an amount effective to deliver the exosomes.
[0093] Embodiment 9 is the method of any one of embodiments 1-8, wherein the surgical mesh is at least 1 cm by 1 cm in size.
[0094] Embodiment 10 is a method according to any one of embodiments 2 to 9, wherein the method results in resolution of mesh exposure as measured by increased cell proliferation, increased epithelial thickness, increased vascularization, or lack of dehiscence compared to untreated mesh exposure.
[0095] Embodiment 11 is a method according to any one of embodiments 1 to 10, wherein the method results in a reduction in scar formation as measured by histomicroscopy compared to untreated mesh exposure.
[0096] Embodiment 12 is the method of any one of embodiments 1-11, wherein administering PEP comprises injecting PEP at one or more sites within the treated area.
[0097] Aspect 13 is the method of any one of embodiments 1 to 12, wherein the PEP is administered in a composition further comprising an extracellular matrix component.
[0098] Embodiment 14 is the method of embodiment 13, wherein the extracellular matrix component comprises collagen. EXAMPLES
[0099] The present invention is illustrated in the following examples, it being understood that the specific examples, materials, amounts and procedures should be interpreted broadly in accordance with the scope and spirit of the invention described herein. EXAMPLES
[0100] A porcine model was used because porcine and human anatomy are similar and the internal diameter and length of the vagina allows for the implantation of multiple clinically relevant sized meshes per animal.
[0101] Mesh Exposed Model Sixteen macroporous monofilament polypropylene meshes (RestorelleM Flat Mesh; Coloplast Corp., Minneapolis, MN) were surgically implanted into the vaginas of seven domestic Yorkshire cross pigs weighing 70-80 kg. Animals were divided into two groups: (group 1) vaginal epithelial reclosure with (N=2) or without (N=2) PEP injection, and (group 2) PEP injection only (N=3).
[0102] The mesh denudation model was created by denuding the vaginal epithelium and underlying fibromuscular tissue with electrocautery, then fixing mesh squares to this area with knotted 2-0 polypropylene sutures. For group 1, a 3 cm x 3 cm mesh was implanted in the ventral and rostral aspects of the vagina. For group 2, meshes of different sizes (1 cm x 1 cm, 2 cm x 2 cm, 3 cm x 3 cm) were implanted in the circumferential direction (Figure 1). After 7–10 days, the animals were returned to the operating room for the interventional procedure.
[0103] Preparation of purified exosome product (PEP) PEP was prepared as previously described (International Patent Application No. PCT / US2018 / 065627, published as International Publication No. WO2019 / 118817).
[0104] The PEP was stored at room temperature until reconstituted for use.
[0105] Interventional Procedures with or without Purified Exosome Products Groups received surgical, exosome, or combined treatment for their mesh exposure. For groups 1A and 1B, the epithelium adjacent to the mesh and the underlying fibromuscular tissue were mobilized and reapproximated without tension in a knotted fashion with 2-0 polyglactin 910 sutures. Group 1B received 2.5 mL of reconstituted PEP injected simultaneously into the mesh and deep to the closure, evenly across the area encompassed by the mesh. Group 2 received PEP injection only, with PEP (2.5 mL) injected under the mesh into the vaginal tissue as described above.
[0106] The 20% PEP gel was prepared by diluting 5 × 10 12 The exosomes were generated by reconstituting lyophilized PEP exosomes (Rion LLC, Rochester, MN) and injected using a 21-gauge needle.
[0107] 2'-Deoxy-5-ethynyluridine (EdU) is incorporated into DNA as a thymidine analogue during DNA replication. It can be used to track tissue regeneration. One animal in the PEP-only group was given it as an oral supplement (5 mg / kg) twice weekly.
[0108] Wild type Unmounted sows of comparable size and age were used for vaginal biopsy and comparison as "wild type". Sacrifice was carried out similarly to the experimental groups.
[0109] Sacrifice and tissue collection Four weeks after the intervention, the animals were euthanized with pentobarbital. The urogenital tract was removed en bloc and photographed. The most central part of the regenerated tissue from each mesh complex was sampled using a scalpel. If no regeneration was observed, peripheral biopsies were taken adjacent to the mesh edge. The tissue specimens were then placed in cassettes and immersed in formalin or tramp fixative.
[0110] Histological processing and quantification The excised samples were processed for transmission electron microscopy (TEM), hematoxylin and eosin (H&E), Masson's trichrome staining, and immunohistochemical staining.
[0111] Formalin-fixed samples were embedded in paraffin and cut into 10 μm sections on a microtome. Sections were subjected to standard histopathological analysis, including hematoxylin and eosin (H&E) and Masson's trichrome staining (Fig. 3A). H&E-stained sections were imaged using a slide scanner (AXIO SCAN.Z1, Carl Zeiss Microscopy GmbH, Jena, Germany). For immunohistochemical analysis, sections were deparaffinized by successive washes in xylene and rehydrated in decreasing amounts of ethanol. Antigen retrieval was performed by immersing sections in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) and boiling for 30 min. Sections were outlined with a hydrophobic pen, blocked with blocking buffer (PBS containing 5% normal donkey serum, 5% bovine serum albumin, and 0.2% Triton-X) for 1 h at room temperature, and incubated overnight at 4 °C with primary antibodies (Table 1) diluted in blocking buffer. Alexa Fluor (Molecular Probes, Inc., Eugene, OR) secondary antibodies (donkey) were diluted 1:500 in blocking buffer and incubated for 1 h at room temperature. EdU was labeled using an imaging kit (Click-iT Plus EdU AF647, Thermo Fisher Scientific, Inc., Waltham, MA) according to the manufacturer's instructions. After extensive washing, ProLong Gold Antifade Mountant with DAPI was added to each section, covered with a cover slip, and imaged under an inverted fluorescence microscope (Axio Observer, Carl Zeiss Microscopy GmbH, Jena, Germany) equipped with a 10x objective. [Table 1]
[0112] Average epithelial thickness was measured from H&E stained sections. Epithelial area was calculated by manually outlining in FIJI (v.2.0) and then divided by epithelial length. Immunofluorescence was quantified using thresholding, mask creation, and particle analysis using FIJI with the GDSC plugin and custom macros. The extent of proliferation was measured as the number of Ki67 per epithelial length in a given 10x field. + The number of cells was assessed by counting. A mask was made using an epithelial marker (pan-cytokeratin) to measure the total Ki67 per epithelial length. + Cell number and epithelial Ki67 cell number were quantified. Non-epithelial proliferation was determined by total Ki67 + The Ki67 ratio was calculated as the difference between the subepithelial area and the epithelial Ki67 ratio. 2 CD31 hit + Angiogenesis was assessed by quantifying the number of vascular lumen CD31 + and SMA + The degree of area co-distribution was used as a surrogate for smooth muscle deposits outside of blood vessels and reported as the intensity correlation index (ICQ). Chronic inflammation was measured by the number of CD3 + It was assessed by measuring the percent area covered by cells (T lymphocytes). Histological processing and quantification was performed by a blinded investigator.
[0113] Ultrasound Vibroelastography Elastography was performed before sacrifice to assess tissue biomechanics in vivo. Harmonic vibrations (100 Hz) of 0.1 s were generated in the perineum using a handheld vibrator (Model FG-142, Labworks Inc., Costa Mesa, CA) as previously described (Zhou et al., 2019. Radiology 291(2):479-484). The excitation signal was amplified by a sound amplifier (Model D150A, Crown Audio Inc., Elkhart, IN) as previously described (Zhou et al., 2017. Ultrasonics 81(Supplement C):86-92). Wave propagation in the vagina was measured on an ultrasound diagnostic device (Verasonics, Inc., Kirkland, WA) using a linear array ultrasound probe (L11-5v, Verasonics, Inc., Kirkland, WA) with a center frequency of 6.4 MHz.
[0114] Velocity maps were obtained and representative shear wave velocities were reported for each mesh. Tissue viscosity was obtained using post-acquisition calculations. Radio frequency data of ultrasound echoes were obtained and demodulated to obtain IQ data of the ultrasound signal. Tissue motion was obtained by using autocorrelation analysis of the ultrasound IQ data as previously described (Zhang et al., 2017. IEEE Trans Ultrason Ferroelectrolyte Frequency Control 64(9):1298-1304). Cross-correlation techniques were used to measure wave velocities in both horizontal and vertical directions, and velocity maps of the region of interest were obtained as previously described (Zhang et al., 2019. IEEE Trans Ultrason Ferroelectr Frequency Control 66(5):1346-1352).
[0115] Measurements of wave velocities at multiple frequencies can be used to calculate the shear elasticity and shear viscosity using the Voigt model,
number
[0116] The shear elasticity and viscosity were determined via a Levenberg-Marquardt nonlinear least-squares algorithm by minimizing the difference between the measured and predicted shear wave velocities at different vibration frequencies as previously described (Prim et al., 2016. J Mec Behav Biomed Mater 54:93-105). The residual error of the objective function was calculated as follows:
number
[0117] Mean wave velocity and viscosity were similar between groups. These findings suggest that PEP does not induce fibrosis-dominant wound healing that leads to unfavorable viscoelastic changes.
[0118] statistical analysis Given the pilot nature of this study, limited statistical analysis was performed. Quantifiable data were reported as mean ± standard deviation. Where appropriate, data were analyzed with one-way ANOVA and post-hoc Tukey's test, with the significance level set at an alpha of 0.05. EXAMPLES
[0119] Experimental design The animals were divided into three groups based on the timing and frequency of PEP injections. Group 1: Single PEP injection 7 days after mesh implantation (Acute-Single, N=1, 2 meshes). Group 2: Weekly PEP injections, starting 7 days after mesh implantation and continuing weekly for a total of 4 weekly injections (Acute-Weekly, 4 injections, N=2, 4 meshes). Group 3: Delayed single PEP injection 8 weeks after mesh implantation (Subacute-Single, N=3, 6 meshes). More animals were assigned to the subacute group to account for possible animal and tissue loss over a longer period of time. Fewer animals were placed in the control group (Acute-Single) due to the uniform data from Example 1. All groups were sacrificed 4 weeks after the first PEP injection (Figure 7). Given previous data suggesting the effectiveness of PEP as a non-surgical treatment for mesh exposure (Example 1, Figures 1-6), none of the groups underwent concurrent surgical closure. All animals received 2′-deoxy-5-ethynyluridine (EdU, Carbosynth LLC, San Diego, CA), a thymidine analogue that is incorporated into replicating DNA, at a dose of 5 mg / kg (10–20 mL orally, twice weekly starting on the day of PEP injection) to monitor cell proliferation.
[0120] Mesh Exposed Model The mesh denudation model was created using the method previously described (Example 1). Briefly, six domestic Yorkshire cross pigs (70-80 kg) were anesthetized and prepared using aseptic technique. Betadine was applied intravaginally and over the perineum and hind limbs. The vaginal epithelium and fibromuscular tissue were mobilized and excised in an area of 3 cm x 3 cm by standard surgical techniques using electrocautery. Macroporous monofilament polypropylene mesh (Restorelle M Flat Mesh; Coloplast Corp., Minneapolis, MN) was cut into 3 cm x 3 cm sections and secured to the denuded areas in the mid-ventral and mid-rostral vagina using knotted 2-0 polyglactin 910 sutures along the lateral borders (2 meshes implanted per pig).
[0121] Injection of purified exosome product (PEP) A working solution of 20% PEP was added to 5 × 10 12Lyophilized PEP exosomes (Rion LLC, Rochester, MN) were generated by reconstitution in 1 mL of sterile water and 4 mL of clinical grade type I bovine collagen (5 mg / mL; Collagen Solutions, Glasgow, UK). After reconstitution, the PEP solution formed a gel-like consistency. After sterile betadine preparation, a total of 2.5 mL of PEP gel was injected into the fibromuscular tissue under each mesh exposure, evenly across nine sites (3 × 3 grid pattern) using a 21-gauge needle.
[0122] Tissue harvesting and histological processing Four weeks after the first PEP injection, all animals were euthanized with pentobarbital. The urogenital tract was excised en bloc and photographed. The most central part of the regenerated vagina-mesh complex was then sampled using a scalpel, placed in a cassette, and immersed in formalin. Formalin-fixed specimens were embedded in paraffin and cut into 10 μm sections on a microtome. Sections were processed for hematoxylin and eosin (H&E) staining and immunohistochemical staining according to standard laboratory protocols. H&E stained sections were imaged using a 10x objective on a Motic EasyScanPro digital slide scanner (Motic Ltd., Hong Kong).
[0123] For immunohistochemical analysis, sections were deparaffinized by successive washes in xylene and rehydrated in decreasing amounts of ethanol. Antigen retrieval was performed by immersing sections in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) and boiling for 30 min. Sections were outlined with a hydrophobic pen, blocked in blocking buffer (PBS containing 5% normal donkey serum, 5% bovine serum albumin, 0.2% Triton-X) for 1 h at room temperature, and incubated overnight at 4°C with primary antibodies (Table 1) diluted in blocking buffer. Alexa Fluor (Molecular Probes, Inc., Eugene, OR) secondary antibodies (raised in donkey) were diluted 1:500 in blocking buffer and incubated for 1 h at room temperature. After completing the secondary antibody labeling, EdU was labeled using the Click-iT Plus EdU AF647 Imaging Kit (Thermo Fisher Scientific, Inc., Waltham, MA) according to the manufacturer's instructions. After extensive washing, ProLong Gold (Thermo Fisher Scientific, Inc., Waltham, MA) antifade mounting medium containing DAPI (4',6-diamidino-2-phenylindole) was added to each section, covered with a coverslip, and imaged under an inverted fluorescence microscope (Axio Observer, Carl Zeiss Microscopy GmbH, Jena, Germany) with a 10x objective. [Table 2]
[0124] Quantification and statistical analysis Epithelial thickness was calculated from whole sections that were automatically stitched from individual images acquired by a slide scanner. Both epithelial area and length in all sections were manually traced using FIJI (v.3.0; Schindelin et al., 2012, Nature Methods 9(7):676-682), and average thickness was reported as the ratio of epithelial area to length. Cell proliferation was measured using a semi-automated custom macro written in FIJI. Briefly, a mask outlining epithelial areas (positive for cytokeratin) was applied to immunofluorescence images co-staining for cytokeratin, EdU, and DAPI. EdU + The number of nuclei was counted within the mask (epithelial proliferation), outside the mask (non-epithelial), and across the entire image (total proliferation). + Because cells are present throughout the entire thickness of the epithelium, proliferation was normalized to the area of the epithelium analyzed. Finally, a manual dual counter was applied to immunofluorescence images co-staining for cytokeratin, CD31, EdU, and DAPI. Capillary density was calculated as the number of CD31 per area of subepithelium (cytokeratin-negative area). + Proliferative capillaries were defined as those containing at least one EdU + Nuclear CD31 + Data were reported as the number of vessels. Data were reported as the mean + / - standard error. Data were analyzed by ANOVA and post-hoc Tukey's test, where appropriate. Significance level was set at an alpha of 0.05.
[0125] The complete disclosures of all patents, patent applications, and publications cited herein, as well as electronically available materials (including, for example, nucleotide sequence deposits in GenBank and RefSeq, and amino acid sequence deposits in SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and RefSeq) are incorporated by reference in their entirety. In the event of any inconsistency between the disclosure of this application and the disclosure of any document incorporated herein by reference, the disclosure of this application shall prevail. The foregoing detailed description and examples are given for clarity of understanding only. They should not be understood as being unnecessarily limiting. The invention is not limited to the exact details shown and described, and variations obvious to one skilled in the art will be included in the invention as defined by the claims.
[0126] Unless otherwise indicated, all numbers expressing quantities of ingredients, molecular weights, and the like used in the specification and claims should be understood to be modified in all instances by the term "about." Accordingly, unless otherwise indicated, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by ordinary rounding techniques.
[0127] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible, however, all numerical values inherently contain ranges necessarily resulting from the standard deviation found in their respective testing measurements.
[0128] All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.
Claims
1. 1. A method for treating surgical mesh exposure in a subject, comprising: A method comprising administering PEP to tissue adjacent to the area of exposed surgical mesh in an amount effective to treat said area of exposed surgical mesh.
2. 1. A method for treating surgical mesh exposure in a subject, comprising: surgically closing the area of exposed surgical mesh; administering PEP to the epithelium adjacent to said surgical closure in an amount effective to treat the area of exposed surgical mesh.
3. 3. The method of claim 1 or 2, wherein the amount effective to treat the area of exposed surgical mesh comprises an amount effective to increase epithelial proliferation to reduce the area of exposed surgical mesh, to increase the thickness of the epithelium overlying the surgical mesh, or to increase vascularization of the epithelium overlying the surgical mesh.
4. The method of any one of claims 1 to 3, wherein the PEP is administered once.
5. The method of any one of claims 1 to 3, wherein the PEP is administered two or more times.
6. 6. The method of claim 5, wherein the PEP is provided in 2 to 4 doses.
7. 7. The method of claim 5 or 6, wherein the PEP is administered with an interval of about 7 days between doses.
8. PEP is at least 10 12 The method of any one of claims 1 to 7, wherein the PEP exosomes are administered in an amount effective to deliver the PEP exosomes.
9. The method of any one of claims 1 to 8, wherein the surgical mesh is at least 1 cm by 1 cm in size.
10. 10. The method of any one of claims 2-9, wherein the method results in resolution of mesh exposure as measured by increased cell proliferation, increased epithelial thickness, increased vascularization, or lack of dehiscence compared to untreated mesh exposure.
11. A method according to any one of claims 1 to 10, wherein the method results in a reduction in scar formation as measured by histomicroscopy compared to untreated mesh exposure.
12. The method of any one of claims 1 to 11, wherein administering PEP comprises injecting PEP at one or more sites within the treated area.
13. The method of any one of claims 1 to 12, wherein the PEP is administered in a composition further comprising an extracellular matrix component.
14. The method of claim 13 , wherein the extracellular matrix component comprises collagen.
